Mithrl has announced a $20 million Series A, led by Obvious Ventures, with participation from Headline, AGI House, and several pharmaceutical executives. The announcement brings up an increasingly important challenge in...read more
Category - Drug discovery
A Single-Cell Map of the Human Immune System Across Lifespan
The status of the human immune system is heavily involved in both disease defense and healthy aging or its converse. At enligtenbio we have an interest in understanding human immune function and how immune changes link...read more
How AI Language Models Are Uncovering Hidden Bacterial Immune Systems
How artificial intelligence is revealing thousands of previously unknown bacterial antiviral defense systems, and why they could become the next generation of biotechnology tools TL;DR: Two recently published science...read more
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across the...read more
